Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maria Livia Del Giudice"'
Autor:
Elisabetta Antonioli, Sofia Pilerci, Irene Attucci, Gabriele Buda, Alessandro Gozzetti, Veronica Candi, Federico Simonetti, Maria Livia Del Giudice, Sara Ciofini, Michela Staderini, Sara Grammatico, Alessandra Buzzichelli, Maria Messeri, Monica Bocchia, Sara Galimberti, Alessandro M. Vannucchi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionCarfilzomib, a potent, irreversible, selective proteasome inhibitor has demonstrated consistent results in relapsed/refractory multiple myeloma (RRMM) combined with lenalidomide and dexamethasone (KRd). No prospective studies are yet avai
Externí odkaz:
https://doaj.org/article/0187b91cd2a6449081286e4dd3695ef6
Autor:
Francesco Mazziotta, Gabriele Buda, Maria Livia Del Giudice, Enrico Orciuolo, Edoardo Benedetti, Matilde Masini, Vincenzo De Tata, Sara Galimberti, Mario Petrini
Publikováno v:
Hematology Reports, Vol 14, Iss 1, Pp 19-23 (2022)
Amyloidosis is a rare disease that is often seen in conjunction with multiple myeloma (MM). Its damage varies depending on the anatomical site affected; however, it is believed that many cases of amyloidosis are misrecognized due to the fact that its
Externí odkaz:
https://doaj.org/article/159faeae7f8e4afea00f5857f68f7209
Autor:
Gabriele Buda, Maria Livia Del Giudice, Elisabetta Antonioli, Francesco Ghio, Enrico Orciuolo, Riccardo Morganti, Francesca Martini, Michela Staderini, Sara Galimberti, Mario Petrini
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Introduction: Currently, the regimen with bortezomib plus melphalan and prednisone (VMP) is a standard treatment for multiple myeloma and it is recommended as the first-line therapy for patients with multiple myeloma (MM) ineligible for high-dose che
Externí odkaz:
https://doaj.org/article/a9130b66ac28496b80b190f3f21f6a6e
Autor:
Maria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, Enrico Orciuolo, Francesco Ghio, Sara Ciofini, Veronica Candi, Giulia Fontanelli, Irene Attucci, Giuseppe Formica, Monica Bocchia, Sara Galimberti, Mario Petrini, Gabriele Buda
Publikováno v:
Medicina, Vol 57, Iss 9, p 900 (2021)
Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and pr
Externí odkaz:
https://doaj.org/article/3fe837b718724a06912df20ad09277e3
Autor:
Maria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, Irene Attucci, Ludovica Pengue, Raffaella Cassano Cassano, Francesco Ghio, Enrico Orciuolo, Martina Simoncelli, Monica Bocchia, Sara Galimberti, Gabriele Buda
Publikováno v:
European Journal of Haematology. 109:373-380
We investigate safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma.We retro-prospective analyzed 75 pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a02543e91a77c9a3f69fde2dcc456c5
https://doi.org/10.1111/ejh.13819
https://doi.org/10.1111/ejh.13819
Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
Autor:
Gozzetti, Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Veronica Candi, Ludovica Pengue, Maria Livia Del Giudice, Irene Attucci, Francesca Bacchiarri, Ubaldo Occhini, Maria Teresa Pirrotta, Federico Perfetto, Monica Bocchia, Alessandro
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 3; Pages: 484
Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::d4d40bacff6214b5f6c46cba1501cd24
Autor:
Maria Livia Del Giudice, Elisabetta Antonioli, Riccardo Morganti, Sara Galimberti, Gabriele Buda, Francesca Martini, Mario Petrini, Michela Staderini, Francesco Ghio, Enrico Orciuolo
Publikováno v:
Frontiers in Medicine
Frontiers in Medicine, Vol 8 (2021)
Frontiers in Medicine, Vol 8 (2021)
Introduction: Currently, the regimen with bortezomib plus melphalan and prednisone (VMP) is a standard treatment for multiple myeloma and it is recommended as the first-line therapy for patients with multiple myeloma (MM) ineligible for high-dose che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6873f3d0d2da2b6a481d51e42bbfac0c
http://hdl.handle.net/11568/1132850
http://hdl.handle.net/11568/1132850
Daratumumab in AL Amyloidosis: A Real-Life Experience of the 'RTM' (Regional Tuscan Myeloma Network)
Autor:
Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Veronica Candi, Ludovica Pengue, Maria Livia Del Giudice, Irene Attucci, Francesca Bacchiarri, Ubaldo Occhini, Maria Teresa Pirrotta, Federico Perfetto, Monica Bocchia, Alessandro Gozzetti
Publikováno v:
Journal of Personalized Medicine. 12:484
Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c1c83ca265ed912dfab28144c43fe6
https://doi.org/10.3390/jpm12030484
https://doi.org/10.3390/jpm12030484